Use the hyperlinks, where available to access additional clinical trial information.
FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
This is a non-randomised study with one experimental arm. Participants will receive DAY101, orally, at a dose of 420mg/m2 once weekly for each 28-day treatment cycle for a planned period of 26 cycles.